SPRO NASDAQ
Spero Therapeutics, Inc.
1W: -3.2%
1M: -2.5%
3M: -45.7%
YTD: -49.4%
1Y: -39.3%
3Y: -0.8%
5Y: -93.7%
$1.19
-0.07 (-5.56%)
Weekly Expected Move ±11.7%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-07-01
Earliest Filing
2022-09-22
Latest Filing
partner: 3
investor: 1
Counterparties (Filed by SPRO)
4 relationshipsCompanies named in SPRO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| GlaxoSmithKline Intellectual Property (No. 3) Limited | — | partner | Licensee granted exclusive rights to develop and commercialize tebipenem HBr products | 2022-09-22 | View |
| Meiji Seika Pharma Co., Ltd. | — | partner | IP holder whose regulatory documents are sublicensed for development in Asian territories | 2022-09-22 | View |
| Glaxo Group Limited | — | investor | Purchased 7,450,000 shares of common stock in a concurrent stock purchase agreement | 2022-09-22 | View |
| Pfizer Inc. | PFE | partner | Licensee and investor in a $40 million stock purchase and product development agreement. | 2021-07-01 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-28 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-07-14 | Material Agreement; Financial Obligation; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-06-25 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-06-22 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-03-26 | Earnings Release; Exhibits | View | |
| 2026-01-30 | Departure/Election of Directors; Appointment of Officers; Other Events | View | |
| 2025-12-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-18 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-28 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-28 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-03-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-28 | Notice of Delisting or Transfer | View | |
| 2025-01-10 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2024-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-29 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; Re | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR